menu
    • menu
    [{"orgOrder":0,"company":"22nd Century Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"22nd Century Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"22nd Century Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"22nd Century Group \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by 22nd Century Group

    Menu

    22nd Century Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            22nd Century Group

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            22nd Century Group

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            22nd Century Group (Nasdaq: XXII) Launches VLN® Reduced Nicotine Content Cigarettes in Colorado with Circle K...

                            Details : With dozens of patent allowing it to control VLN (nicotine) biosynthesis in tobacco plant, Company has developed proprietary reduced nicotine content tobacco plant and cigarette, which become FDA’s Comprehensive Plan to address widespread death and dis...

                            Product Name : VLN

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 09, 2022

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            22nd Century Group

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            22nd Century Group

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Vince & Associates Clinical Research, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 18, 2018

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Vince & Associates Clinical Research, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            22nd Century Group

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            22nd Century Group

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Vince & Associates Clinical Research, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 18, 2018

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Vince & Associates Clinical Research, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth